TrialCurveESCAPE (metastatic renal cell carcinoma): reconstructed Kaplan–Meier curves
Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Cancers (Basel). 2023 May 13;15(10):2745. doi: 10.3390/cancers15102745 |
|---|---|
| DOI | 10.3390/cancers15102745 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
2nd-line progression-free survival
From figure panel B · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Sunitinib 3.8 months; IL-2+IFNα 15.3 months. Survival at 12 months: Sunitinib 40%; IL-2+IFNα 61%. Hazard ratio IL-2+IFNα vs Sunitinib 0.58 (95% CI 0.19–1.76).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Sunitinib | 5 | 5 | 3.8 |
| IL-2+IFNα | 13 | 9 | 15.3 |
- IL-2+IFNα vs Sunitinib: reconstructed HR 0.58 (95% CI 0.19–1.76)
Landmark survival (reconstructed)
| Time | Sunitinib | IL-2+IFNα |
|---|---|---|
| 6 mo | 40.0% | 69.2% |
| 12 mo | 40.0% | 60.6% |
| 18 mo | 20.0% | 40.4% |
| 24 mo | — | 20.2% |
| 36 mo | — | 20.2% |
Checks against the published figure
- Sunitinib median: printed 3.7, reconstructed 3.75 pass
- IL-2+IFNα median: printed 14.7, reconstructed 15.3 pass
- hazard ratio (direction inferred): printed 0.595, reconstructed 0.584 pass
1st-line (+ 2nd-line) progression-free survival — Including cases who did not receive 2nd-line treatment
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: IL-2+IFNα 30.3 months; Sunitinib 28.6 months. Survival at 18 months: IL-2+IFNα 71%; Sunitinib 68%. Hazard ratio IL-2+IFNα vs Sunitinib 0.89 (95% CI 0.29–2.77).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| IL-2+IFNα | 17 | 8 | 30.3 |
| Sunitinib | 13 | 5 | 28.6 |
- IL-2+IFNα vs Sunitinib: reconstructed HR 0.89 (95% CI 0.29–2.77)
Landmark survival (reconstructed)
| Time | IL-2+IFNα | Sunitinib |
|---|---|---|
| 6 mo | 93.8% | 100.0% |
| 12 mo | 87.1% | 79.5% |
| 18 mo | 71.2% | 68.2% |
| 24 mo | 71.2% | 68.2% |
| 36 mo | 36.9% | — |
| 48 mo | 36.9% | — |
| 60 mo | 36.9% | — |
Checks against the published figure
- Sunitinib median: printed 27.6, reconstructed 28.6 pass
- IL-2+IFNα median: printed 30.3, reconstructed 30.3 pass
- hazard ratio (direction inferred): printed 0.83, reconstructed 0.893 pass
Overall survival
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Sunitinib 69.2 months; IL-2+IFNα not reached. Survival at 18 months: Sunitinib 92%; IL-2+IFNα 81%. Hazard ratio Sunitinib vs IL-2+IFNα 0.60 (95% CI 0.15–2.39).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Sunitinib | 13 | 3 | 69.2 |
| IL-2+IFNα | 17 | 6 | not reached |
- Sunitinib vs IL-2+IFNα: reconstructed HR 0.60 (95% CI 0.15–2.39)
Landmark survival (reconstructed)
| Time | Sunitinib | IL-2+IFNα |
|---|---|---|
| 6 mo | 92.3% | 100.0% |
| 12 mo | 92.3% | 93.8% |
| 18 mo | 92.3% | 81.2% |
| 24 mo | 92.3% | 75.0% |
| 36 mo | 92.3% | 75.0% |
| 48 mo | 92.3% | 67.5% |
| 60 mo | 80.8% | 59.1% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.68, reconstructed 1.67 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- AMPLITUDE: Investigator-assessed radiographic progression-free survival; Overall survival; Radiograph
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials